Influenza Drug Global Market Report 2026

Description

An influenza drug is a medication used to prevent or treat influenza (flu) by targeting the influenza virus. These drugs function through various mechanisms, such as inhibiting viral replication, blocking viral entry into host cells, or enhancing the immune response against the virus.

The main types of influenza drugs include those targeting influenza A, influenza B, and influenza C. Influenza A infects humans and various animals, causing seasonal flu epidemics and, occasionally, pandemics. These drugs can be administered via oral, intranasal, intravenous, intramuscular, or subcutaneous routes and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The mechanisms of action include neuraminidase inhibitors, cap-dependent endonuclease inhibitors, fusion inhibitors, M2 ion channel inhibitors, host cell protease inhibitors, immunomodulatory agents, RNA polymerase inhibitors, hemagglutinin stem binders, cytokine inhibitors, and host factor-targeting strategies. Key end users include hospitals and clinics, pharmacies, vaccination centers, research institutions, government health agencies, long-term care facilities, community health centers, and corporate health programs.

Tariffs have affected the influenza drug market by increasing costs of imported antiviral drugs, biologics, and diagnostic devices, which has disrupted supply chains and slowed market growth. Hospital pharmacies, retail pharmacies, and vaccination centers in regions like North America and Europe, which rely heavily on imports, are most affected. However, tariffs have also encouraged local manufacturing, innovation in antiviral formulations, and investment in domestic production, potentially leading to more cost-effective and accessible influenza treatments.

The influenza drug market research report is one of a series of new reports from The Business Research Company that provides influenza drug market statistics, including influenza drug industry global market size, regional shares, competitors with a influenza drug market share, detailed influenza drug market segments, market trends and opportunities, and any further data you may need to thrive in the influenza drug industry. This influenza drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The influenza drug market size has grown strongly in recent years. It will grow from $1.04 billion in 2025 to $1.11 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to seasonal influenza outbreaks, rising global influenza incidence, development of first-generation antiviral drugs, growing hospital and clinic infrastructure, increasing public awareness about flu prevention.

The influenza drug market size is expected to see strong growth in the next few years. It will grow to $1.4 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to launch of next-generation antiviral therapies, expansion of vaccination campaigns, adoption of digital health monitoring tools, increasing government initiatives for flu prevention, growth in research on host-targeted therapies. Major trends in the forecast period include increasing adoption of rapid diagnostic testing for influenza, rising demand for broad-spectrum antiviral drugs, expansion of vaccination programs and preventive care initiatives, integration of telemedicine and remote patient monitoring, growth in personalized and targeted influenza therapies.

The rising incidence of influenza infections is expected to drive the growth of the influenza drug market in the coming years. Influenza is a contagious respiratory illness caused by influenza viruses, leading to symptoms such as fever, cough, sore throat, and body aches. The increase in cases is largely due to frequent viral mutations that reduce vaccine effectiveness and heighten population vulnerability to outbreaks. Influenza drugs play a critical role in addressing this challenge by offering effective treatment options that lessen disease severity and help control transmission. For example, in September 2023, the Centers for Disease Control and Prevention (CDC), a US public health agency, reported that during the 2022-2023 season, influenza infections in the United States caused 31 million symptomatic illnesses, 14 million medical visits, 360,000 hospitalizations, and 21,000 deaths. As a result, the rising incidence of influenza infections is fueling demand for influenza drugs.

Companies in the influenza drug market are focusing on technological advancements, particularly in drug formulation, to improve treatment effectiveness, patient compliance, and overall therapeutic outcomes. Drug formulation involves combining excipients and inert materials with active pharmaceutical ingredients (APIs) to create drug products with desired properties. For instance, in August 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical and diagnostics company, introduced Baloxavir Marboxil for Suspension, a strawberry-flavored, single-dose oral antiviral designed for children. This product enables accurate weight-based dosing, making administration easier for parents and improving compliance. It provides a convenient home-based treatment option aligned with prescription delivery services, though resistance may develop over time, particularly among pediatric patients.

In July 2024, GlaxoSmithKline plc, a Netherlands-based pharmaceutical company, partnered with CureVac N.V. to strengthen its mRNA vaccine platform. Through this collaboration, GSK aimed to accelerate the development of COVID-19 and influenza vaccine candidates and expand its infectious-disease pipeline. CureVac N.V., based in Germany, specializes in developing influenza drugs and advanced vaccine technologies.

Major companies operating in the influenza drug market are F. Hoffmann-La Roche Ltd., Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Shionogi & Co. Ltd., Green Cross Corp, Emergent BioSolutions Inc., BioCryst Pharmaceuticals Inc., SAB Biotherapeutics Inc., Viriom Inc., Cocrystal Pharma Inc.

North America was the largest region in the influenza drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the influenza drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The influenza drug market consists of sales of oseltamivir phosphate, rimantadine, zanamivir, baloxavir marboxil and favipiravir (avigan or fabiflu). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Influenza Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses influenza drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for influenza drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The influenza drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Type: Influenza A; Influenza B; Influenza C
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Route Of Administration: Oral; Intranasal; Intravenous
4) By Mechanism Of Action: Neuraminidase Inhibitors; Cap-Dependent Endonuclease Inhibitors; Fusion Inhibitors; M2 Ion Channel Inhibitors; Host Cell Protease Inhibitors; Immunomodulatory Agents; Ribonucleic Acid (RNA) Polymerase Inhibitors; Hemagglutinin Stem Binders; Host Factor Targeting
5) By End-User: Hospitals And Clinics; Pharmacies; Research Institutions; Government Health Agencies; Long-Term Care Facilities; Community Health Centers; Corporate Health Programs
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Pfizer Inc.; AstraZeneca PLC; GlaxoSmithKline plc; Daiichi Sankyo Co. Ltd.; Shionogi & Co. Ltd.; Green Cross Corp; Emergent BioSolutions Inc.; BioCryst Pharmaceuticals Inc.; SAB Biotherapeutics Inc.; Viriom Inc.; Cocrystal Pharma Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH4MIDRU04_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Influenza Drug Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Influenza Drug Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Influenza Drug Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Influenza Drug Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Artificial Intelligence & Autonomous Intelligence
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Increasing Adoption Of Rapid Diagnostic Testing For Influenza
- 4.2.2 Rising Demand For Broad-Spectrum Antiviral Drugs
- 4.2.3 Expansion Of Vaccination Programs And Preventive Care Initiatives
- 4.2.4 Integration Of Telemedicine And Remote Patient Monitoring
- 4.2.5 Growth In Personalized And Targeted Influenza Therapies

5. Influenza Drug Market Analysis Of End Use Industries

5.1 Hospitals And Clinics
5.2 Pharmacies
5.3 Vaccination Centers
5.4 Research Institutions
5.5 Government Health Agencies

6. Influenza Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Influenza Drug Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Influenza Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Influenza Drug Market Size, Comparisons And Growth Rate Analysis
7.3. Global Influenza Drug Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Influenza Drug Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Influenza Drug Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Influenza Drug Market Segmentation

9.1. Global Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Influenza A, Influenza B, Influenza C
9.2. Global Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
9.3. Global Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Intranasal, Intravenous
9.4. Global Influenza Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Neuraminidase Inhibitors, Cap-Dependent Endonuclease Inhibitors, Fusion Inhibitors, M2 Ion Channel Inhibitors, Host Cell Protease Inhibitors, Immunomodulatory Agents, Ribonucleic Acid (RNA) Polymerase Inhibitors, Hemagglutinin Stem Binders, Host Factor Targeting
9.5. Global Influenza Drug Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals And Clinics, Pharmacies, Research Institutions, Government Health Agencies, Long-Term Care Facilities, Community Health Centers, Corporate Health Programs

10. Influenza Drug Market Regional And Country Analysis

10.1. Global Influenza Drug Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Influenza Drug Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Influenza Drug Market

11.1. Asia-Pacific Influenza Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Influenza Drug Market

12.1. China Influenza Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Influenza Drug Market

13.1. India Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Influenza Drug Market

14.1. Japan Influenza Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Influenza Drug Market

15.1. Australia Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Influenza Drug Market

16.1. Indonesia Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Influenza Drug Market

17.1. South Korea Influenza Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Influenza Drug Market

18.1. Taiwan Influenza Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Influenza Drug Market

19.1. South East Asia Influenza Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Influenza Drug Market

20.1. Western Europe Influenza Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Influenza Drug Market

21.1. UK Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Influenza Drug Market

22.1. Germany Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Influenza Drug Market

23.1. France Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Influenza Drug Market

24.1. Italy Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Influenza Drug Market

25.1. Spain Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Influenza Drug Market

26.1. Eastern Europe Influenza Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Influenza Drug Market

27.1. Russia Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Influenza Drug Market

28.1. North America Influenza Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Influenza Drug Market

29.1. USA Influenza Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Influenza Drug Market

30.1. Canada Influenza Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Influenza Drug Market

31.1. South America Influenza Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Influenza Drug Market

32.1. Brazil Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Influenza Drug Market

33.1. Middle East Influenza Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Influenza Drug Market

34.1. Africa Influenza Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Influenza Drug Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Influenza Drug Market Regulatory and Investment Landscape

36. Influenza Drug Market Competitive Landscape And Company Profiles

36.1. Influenza Drug Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Influenza Drug Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Influenza Drug Market Company Profiles
- 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Daiichi Sankyo Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Influenza Drug Market Other Major And Innovative Companies

Shionogi & Co. Ltd., Green Cross Corp, Emergent BioSolutions Inc., BioCryst Pharmaceuticals Inc., SAB Biotherapeutics Inc., Viriom Inc., Cocrystal Pharma Inc.

38. Global Influenza Drug Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Influenza Drug Market

40. Influenza Drug Market High Potential Countries, Segments and Strategies

40.1 Influenza Drug Market In 2030 - Countries Offering Most New Opportunities
40.2 Influenza Drug Market In 2030 - Segments Offering Most New Opportunities
40.3 Influenza Drug Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer